[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3917 Introduced in House (IH)]

111th CONGRESS
  1st Session
                                H. R. 3917

   To amend title XVIII of the Social Security Act to modernize and 
improve the Medicare payment methodology for radiopharmaceuticals under 
   the hospital outpatient prospective payment system and to ensure 
 equitable payment and patient access to certain low volume, high cost 
                         radiopharmaceuticals.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 22, 2009

 Mr. Stupak (for himself and Mr. Pitts) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
    addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
   To amend title XVIII of the Social Security Act to modernize and 
improve the Medicare payment methodology for radiopharmaceuticals under 
   the hospital outpatient prospective payment system and to ensure 
 equitable payment and patient access to certain low volume, high cost 
                         radiopharmaceuticals.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Nuclear Medicine Payment 
Group Clarification Act of 2009''.

SEC. 2. PAYMENT GROUP STANDARDS FOR NUCLEAR MEDICINE PROCEDURES AND 
              RADIOPHARMACEUTICALS.

    (a) In General.--The last sentence of section 1833(t)(2) of the 
Social Security Act (42 U.S.C. 1395l(t)(2)) is amended--
            (1) by inserting ``, including for a nuclear medicine group 
        the cost of any associated diagnostic radiopharmaceutical that 
        is included in the payment for the service'' after ``(or mean 
        cost, if so elected) for an item or service within the group''; 
        and
            (2) by inserting ``or in the case of services within a 
        nuclear medicine group'' after ``Federal Food, Drug and 
        Cosmetic Act''.
    (b) Effective Date.--The amendments made by subsection (a) shall 
apply to items and services furnished on or after January 1, 2010.
                                 <all>